GT Medical Technologies, Inc. today announced it has entered into a strategic distribution partnership with Theragenics Corporation® (Theragenics), a global leader in minimally invasive brachytherapy.
In a bid to improve competition in the industry, the U.S. Federal Trade Commission is challenging the patents of 20 different pharmaceutical products, disputing the accuracy and relevance of their patents.
Kazia Therapeutics Limited is pleased to announce that the Safety Review Team (SRT) of the EVT801 Phase 1 clinical trial has concluded that the primary and secondary objectives of stage 1 of the trial have successfully been met.
Lipocine Inc. today announced that dosing of subjects has been completed in the pivotal pharmacokinetic (PK) study designed to support a New Drug Application (NDA) for LPCN 1154.
Moleculin Biotech, Inc. today announced the formation of its Annamycin Scientific Advisory Board and inaugural appointment of Dr. Martin Tallman.
Natera, Inc., a global leader in cell-free DNA and genetic testing, announced the launch of a new cfDNA-based fetal RhD test.
Summit Therapeutics Inc. reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024.
Precision BioSciences, Inc. announced that the company will present late-breaking preclinical data from its clinical candidate, PBGENE-HBV, for the treatment of chronic hepatitis B during a poster presentation at the European Association for Study of the Liver Congress 2024 being held June 5-8, 2024 in Milan, Italy.
REGENXBIO Inc. announced that it will host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2024, and recent operational highlights.
Luxa Biotechnology, a joint venture between Y2 Solution Co. Ltd, Seoul, South Korea and the Neural Stem Cell Institute in Rensselaer, New York, announced receipt of a $4 million grant from the California Institute for Regeneration Medicine to support the ongoing Phase 1/2a study of RPESC-RPE-4W transplantation for the treatment of dry age-related macular degeneration.
